Interleukin-1 and tumor necrosis factor-alpha: Novel targets for immunotherapy in eales disease

Ocular Immunology and Inflammation

Volumn 17, Issue 3, 2009, Pages 201-206

  Saxena, Sandeep ^a   Pant, Aditya B ^b   Khanna, Vinay K ^b   Agarwal, A K ^b   Singh, Kamlesh ^a   Kumar, Dipak ^a   Singh, Vijay K ^c  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^c ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

Author keywords

Cytokines; Eales disease; Interleukin; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; EALES DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; INFLAMMATION; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; QUANTITATIVE ANALYSIS;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; RECURRENCE; RETINAL HEMORRHAGE; RETINAL VASCULITIS; TUMOR NECROSIS FACTOR-ALPHA; VITREOUS HEMORRHAGE;

EID: 68849127979     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940902731015     Document Type: Article

References (22)

1. Gieser SC, Murphy RP. Eales' disease. In: Ryan SJ, ed. Retina, Vol II: Medical Retina. St. Louis: CV Mosby; 1994: 1503-1507.
2. Atmaca LS, Idil A, Gunduz K. Visualization of retinal vasculitis in Eales disease. Ocul Immunol Inflammol. 1993;1:41-48.
3. Bali T, Saxena S, Kumar D, Nath R. Response time and efficacy of oral methotrexate pulsed therapy in idiopathic retinal periphlebitis. Eur J Ophthalmol. 2005;15:374-378.
4. Saxena S, Rajasingh J, Biswas S, Kumar D, Shinohara T, Singh VK. Cellular response to retinal S-antigen and interphotoreceptor retinoid binding protein fragments in patients with Eales' disease. Pathobiology. 1999;67:37-44.
5. Saxena S, Srivastava P, Kumar D, Khanna VK, Seth PK. Decreased platelet membrane fluidity in retinal periphlebitis in Eales' disease. Ocul Immunol Inflamm. 2006;14:113-116.
6. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S. Eales disease-an update. Surv Ophthalmol. 2002; 47: 197-214.
7. Saxena S, Kumar D. A new staging system for idiopathic retinal periphlebitis. Eur J Ophthalmol. 2004;14:236-239.
8. Rai G, Saxena S, Kumar H, Singh VK. Human retinal S-antigen: T cell epitope mapping in posterior uveitis patients. Exp Mol Pathol. 2001;70:140-145.
9. Tripathi P, Saxena S, Yadav VS, Naik S, Singh VK. Human Santigen: peptide determinant recognitioninuveitis patients. Exp Mol Pathol. 2004;76:122-128.
10. Armstrong D, Ueda T, Ueda T, et al. Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis. 1998;2:93-104.
11. Kramer M, Monselise Y, Bahar I, et al. Serum cytokine levels in active uveitis and remission. Curr Eye Res. 2007;32:669-675.
12. Hussein MR, Fathi NA, El-Din AM, et al. Alterations of the CD4(+), CD8(+) T cell subsets, interleukins-1beta, IL-10, IL-17, tumor necrosis factor-alpha and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis:preliminary observations. Pathol Oncol Res. 2008;14:321-328.
13. Reimers JI, Bjerre U, Mandrup-Poulsen T, et al. Interleukin-1beta induces diabetes and fever in normal rats by nitric oxide via induction of different nitric oxide synthases. Cytokine. 1994;6:512-520.
14. Rajesh M, Sulochana KN, Punitham R, Biswas J, Lakshmi S, Ramakrishnan S. Involvement of oxidative and nitrosative stress in promoting retinal vasculitis in patients with Eales' disease. Clin Biochem. 2003;36:377-385.
15. Nishimura T, Goodnight R, Prendergast RA, Ryan SJ. Activated macrophages in experimental subretinal neovascularization. Ophthalmologica. 1990;200: 39-44.
16. Yoshida S, Yoshida A, Ishibashi T. Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation. Graefes Arch Clin Exp Ophthalmol. 2004;242:409-413.
17. Inomata H, Ishibashi T, Murata T, Iwasaki M, Tahara A, Hata K, et al. Intraocular neovascularization. Nippon Ganka Gakkai Zasshi. 1997;101:906-926.
18. Kawashima M, Shoji J, Kamura Y, SatoY. Role of chemokines in the vitreous of proliferative diabetic retinopathy. Nippon Ganka Gakkai Zasshi. 2005;109:596-602.
19. Barton, BE, Shortall, J, Jackson, JV. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun. 1996;64:714-718.
20. Libert, C, Takahashi, N, Cauwels, A, et al. Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur J Immunol. 1994;24:2237-2242.
21. Xing, Z, Gauldie, J, Cox, G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101:311-320.
22. Funatsu H, Yamashita H, Shimizu E, Kojima R, Hori S. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina. 2001;21:469-477.